In certain tumors, the expression of plectin and/or its cellular distribution is upregulated, e.g., pancreatic ductal adenocarcinoma, non-small cell lung cancer, high-grade epithelial ovarian cancer, prostate cancer, and head and neck squamous cell carcinoma; in the latter case correlating with a lower survival rate [20–27]. This evidence concerns the gene PLEC and prostate carcinoma.